Thermo Fisher’s $1.075 Billion Sale of its Microbiology Business to Astorg
April 27, 2026
On April 27, 2026, Thermo Fisher Scientific Inc. (“Thermo Fisher”), the world leader in serving science, announced that it has signed a definitive agreement to sell its microbiology business, which provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing, to Astorg, a leading pan‑European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. Cravath is representing Thermo Fisher in connection with the transaction.
The Cravath team was led by partner Ting S. Chen and includes of counsel Joseph A. Marshall and associates Joshua Kameel, Julia Nagle, Debbie Park and Y. Grace Lin on M&A matters; partner Lauren Angelilli and associates Megan Samayoa and Ruth Goldstein Schapiro on tax matters; partner Matthew J. Bobby, senior attorney Aaron S. Cha and associate Caroline Wyatt on executive compensation and benefits matters; partner George E. Zobitz and associate Emily E. Gust on financing matters; partner David J. Kappos and associates Albert Wong and Pierre Schlaefli on intellectual property matters; partner Matthew Morreale and associate Star S. Gulant on environmental matters; and of counsels Joyce Law and Brian M. Budnick on real estate matters. Scarlett A. Neely also worked on executive compensation and benefits matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2006, Stanford Law School
-
A.B., 2003, Harvard CollegePhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
-
J.D., 2000, Harvard Law Schoolcum laude
-
B.S., 1996, The Wharton School of the University of Pennsylvaniamagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2012, Harvard Law Schoolmagna cum laude
-
M.A., 2009, University of Pennsylvania
-
B.A., 2009, University of PennsylvaniaPhi Beta Kappa, summa cum laude
- New York
Education
Admitted In
-
J.D., 1995, New York University School of Lawwith Honors, cum laude
-
B.A., 1991, Franklin & Marshall College
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 1997, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.S., 1994, University of Pennsylvania
-
B.A., 1990, University of Pennsylvania
-
B.A.S., 1990, University of Pennsylvania
- New York
Education
Admitted In
-
J.D., 2018, Northwestern University Pritzker School of Lawcum laude
-
M.B.A., 2018, Northwestern Universitycum laude
-
B.S., 2009, United States Military Academy
- New York
Education
Admitted In
- Photo
-
-
LL.M., 2013, New York University School of Law
-
J.D., 2012, Loyola Law School Los Angeles
-
B.S., 2004, University of California, San Diego
- New York
- California
Education
Admitted In
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
- New York
Education
Admitted In
- Photo
-
-
J.D., 2011, Benjamin N. Cardozo School of Lawcum laude
-
B.A., 2006, University of Virginia
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 31, 2026
Biogen’s $5.6 Billion Acquisition of Apellis
On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.
Deals & Cases
March 11, 2026
Elsevier’s Acquisition of Mytonomy
On March 10, 2026, Elsevier, a global leader in advanced information and decision support and part of RELX, announced it has entered into a definitive agreement to acquire Mytonomy, a leader in video-based patient engagement solutions that will complement Elsevier’s Clinical Solutions portfolio. Cravath is representing RELX in connection with the transaction.
Deals & Cases
March 09, 2026
Talkspace’s Acquisition by UHS
On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.
Deals & Cases
March 02, 2026
Select Medical’s $3.9 Billion Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson and WCAS
On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.
